JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB185194

Anti-PCSK9 antibody [EPR17827-117]

Be the first to review this product! Submit a review

|

(16 Publications)

Anti-PCSK9 antibody [EPR17827-117] (ab185194) is a rabbit monoclonal antibody detecting PCSK9 in Western Blot, Flow Cytometry (Intra), Flow Cytometry, IP, ICC/IF. Suitable for Mouse.

- Biophysical QC for unrivalled batch-batch consistency

View Alternative Names

Narc1, Pcsk9, Proprotein convertase subtilisin/kexin type 9, Neural apoptosis-regulated convertase 1, Proprotein convertase 9, Subtilisin/kexin-like protease PC9, NARC-1, PC9

4 Images
Immunocytochemistry/ Immunofluorescence - Anti-PCSK9 antibody [EPR17827-117] (AB185194)
  • ICC/IF

Unknown

Immunocytochemistry/ Immunofluorescence - Anti-PCSK9 antibody [EPR17827-117] (AB185194)

Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized Hepa1-6 (mouse hepatoma epithelial cell line) cells labeling PCSK9 with ab185194 at 1/100 dilution, followed by Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077) secondary antibody at 1/1000 dilution (green). Confocal image showing cytoplasmic staining in Hepa1-6 cell line is observed.

The nuclear counter stain is DAPI (blue). Tubulin is detected with Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) (ab195889) (red) at 1/200 dilution.

Secondary antibody only control : Used PBS instead of primary antibody, secondary antibody is an Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077) secondary antibody at 1/1000 dilution.

Flow Cytometry (Intracellular) - Anti-PCSK9 antibody [EPR17827-117] (AB185194)
  • Flow Cyt (Intra)

Unknown

Flow Cytometry (Intracellular) - Anti-PCSK9 antibody [EPR17827-117] (AB185194)

Intracellular flow cytometric analysis of 4% paraformaldehyde-fixed, 90% methanol permeabilized Hepa1-6 (mouse hepatoma epithelial cell line) cell line labeling PCSK9 with ab185194 at 1/500 dilution (red) compared with aRabbit IgG, monoclonal [EPR25A] - Isotype Control (ab172730) (black) and an unlabeled control (cells without incubation with primary antibody and secondary antibody) (blue). Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077) at 1/2000 dilution was used as the secondary antibody.

Immunoprecipitation - Anti-PCSK9 antibody [EPR17827-117] (AB185194)
  • IP

Unknown

Immunoprecipitation - Anti-PCSK9 antibody [EPR17827-117] (AB185194)

PCSK9 was immunoprecipitated from 0.35 mg Hepa1-6 (mouse hepatoma epithelial cell line) whole cell lysate with ab185194 at 1/30 dilution. Western blot was performed from the immunoprecipitate using ab185194 at 1/1000 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366) was used for detection at 1/5000 dilution.

Lane 1 : Hepa1-6 whole cell lysate 10 μg (input).
Lane 2 : ab185194 IP in Hepa1-6 whole cell lysate (+).
Lane 3 : Rabbit monoclonal IgG in Hepa1-6 whole cell lsyate (-).

Blocking and dilution buffer and concentration : 5% NFDM/TBST.
Exposure time : 5 seconds.

78-kDa band represents proPCSK9 (PMID : 25210046).

All lanes:

Immunoprecipitation - Anti-PCSK9 antibody [EPR17827-117] (ab185194)

Predicted band size: 74 kDa

false

Western blot - Anti-PCSK9 antibody [EPR17827-117] (AB185194)
  • WB

Unknown

Western blot - Anti-PCSK9 antibody [EPR17827-117] (AB185194)

Exposure time : Lanes 1-3 : 3 minutes; Lane 4 : 6 seconds.

Blocking/diluting buffer and concentration : 5% NFDM/TBST

The expression profile/ molecular weight observed is consistent with what has been described in the literature (PMID : 26092101).

All lanes:

Western blot - Anti-PCSK9 antibody [EPR17827-117] (ab185194) at 1/1000 dilution

Lane 1:

Mouse kidney tissue lysate at 20 µg

Lane 2:

Mouse liver tissue lysate at 20 µg

Lane 3:

Mouse placenta tissue lysate at 20 µg

Lane 4:

Hepa1-6 (mouse hepatoma epithelial cell line) whole cell lysate at 20 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution

Predicted band size: 74 kDa

Observed band size: 60 kDa

false

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR17827-117

Isotype

IgG

Carrier free

No

Reacts with

Mouse

Applications

IP, ICC/IF, Flow Cyt (Intra), WB

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IP" : {"fullname" : "Immunoprecipitation", "shortname":"IP"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"}, "FlowCytIntra" : {"fullname" : "Flow Cytometry (Intracellular)", "shortname":"Flow Cyt (Intra)"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Mouse": { "IP-species-checked": "testedAndGuaranteed", "IP-species-dilution-info": "1/30", "IP-species-notes": "<p></p>", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "<p></p>", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "<p></p>", "ICCIF-species-checked": "testedAndGuaranteed", "ICCIF-species-dilution-info": "1/100", "ICCIF-species-notes": "<p></p>", "FlowCytIntra-species-checked": "testedAndGuaranteed", "FlowCytIntra-species-dilution-info": "1/500", "FlowCytIntra-species-notes": "<p></p>" } } }

Product details

What is this antibody validated in?
Anti-PCSK9 antibody [EPR17827-117] (ab185194) is a rabbit recombinant monoclonal antibody and is validated for use in Western Blot (WB), Flow Cytometry (Intra), Flow Cytometry (Flow Cyt), Immunoprecipitation (IP), Immunocytochemistry/immunofluorescence (ICC/IF) in Mouse samples.

What is the molecular weight of PCSK9?
Anti-PCSK9 [EPR17827-117] (ab185194) specifically detects a band for PCSK9 (UniProt: Q80W65) at a molecular weight of 74kDa.

Trial sizes available!
Test your antibody or perform pre-screening before committing to a larger quantity. Sold in 10µl. Discover our selection of trial-size antibodies.

Other related products
We have a range of other formats of antibody clone [EPR17827-117] also available for your convenience: ab185194, Carrier free - ab242847, Carrier free - ab246322, Alexa Fluor® 488 - ab319077, Alexa Fluor® 647 - ab322020

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a protein responsible for the regulation of cholesterol levels by binding to low-density lipoprotein receptors (LDLR) on hepatocytes. This interaction marks the LDLRs for degradation reducing the liver's ability to clear LDL cholesterol from the blood. PCSK9 has a molecular weight of approximately 74 kDa. The protein is mainly expressed in the liver but is also found in the intestine and kidneys. PCSK9 is referred to as NARC-1 standing for neural apoptosis-regulated convertase 1 highlighting its role in the liver's cholesterol management system.
Biological function summary

PCSK9 influences cholesterol homeostasis by its important role in degrading LDL receptors. It functions independently rather than as part of larger protein complexes. PCSK9 gains particular interest in therapeutic contexts where its inhibition can lead to increased LDLR levels and enhanced clearance of LDL cholesterol. Biotinylated PCSK9 and mouse PCSK9 variants provide significant tools for experimental study. Kits such as the PCSK9 ELISA kit enable detailed measurement of PCSK9 levels in blood samples providing insights into cholesterol metabolism dynamics.

Pathways

PCSK9 operates within the lipid metabolism pathway and the cholesterol biosynthesis pathway. The protein's activity affects the fate of LDL cholesterol within these pathways. It interacts with proteins such as apolipoprotein B (ApoB) which plays a central role in the structural component of LDL particles. The modulation of these pathways by PCSK9 highlights the significance of its function in maintaining cardiovascular health and managing cholesterol levels.

PCSK9 is closely linked to hypercholesterolemia and coronary artery disease. Mutations in PCSK9 can lead to autosomal dominant hypercholesterolemia due to its effect on LDL receptor degradation. Other proteins such as ApoB and LDLR are involved in these conditions tightly interacting with PCSK9's regulatory function. A better understanding of PCSK9's role offers potential therapeutic targets for cardiovascular disease interventions especially through the development of PCSK9 antibodies and PCSK9 assays that adjust cholesterol levels.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members : low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments. Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation. Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway. Inhibits epithelial Na(+) channel (ENaC)-mediated Na(+) absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways.
See full target information Pcsk9

Publications (16)

Recent publications for all applications. Explore the full list and refine your search

iScience 28:112661 PubMed40502707

2025

Telomere attrition alters extracellular vesicles conferring adverse impacts on neuronal viability and inflammatory response.

Applications

Unspecified application

Species

Unspecified reactive species

Yi Gong,Yunong Wang,Francheska Delgado-Peraza,Carlos Nogueras-Ortiz,Nicole Noren Hooten,Deborah L Croteau,Mithlesh Temre,Abigail E Molnar,Monica Bodogai,Ainslee Zou,Kotb Abdelmohsen,Wei Zhu,Yongqing Zhang,Myriam Gorospe,Nan-Ping Weng,Michele K Evans,Dimitrios Kapogiannis,Yie Liu

Nature biotechnology : PubMed40335752

2025

Evolution-guided protein design of IscB for persistent epigenome editing in vivo.

Applications

Unspecified application

Species

Unspecified reactive species

Soumya Kannan,Han Altae-Tran,Shiyou Zhu,Peiyu Xu,Daniel Strebinger,Rachel Oshiro,Guilhem Faure,Lukas Moeller,Julie Pham,Kepler S Mears,Heyuan M Ni,Rhiannon K Macrae,Feng Zhang

Experimental and therapeutic medicine 29:46 PubMed39885913

2025

Lindl. alkaloids improve lipid metabolism by increasing LDL uptake through regulation of the LXRα/IDOL/LDLR pathway and inhibition of PCSK9 expression in HepG2 cells.

Applications

Unspecified application

Species

Unspecified reactive species

Jian Sun,Hao-Rui Liu,Ya-Xin Zhu,Wei Zhang,Jing-Shan Shi,Qin Wu,Rui-Xia Xu

Journal of biochemical and molecular toxicology 38:e70011 PubMed39400940

2024

miR-148a-3p mitigation of coronary artery disease through PCSK9/NF-κB inhibition of vascular endothelial cell injury.

Applications

Unspecified application

Species

Unspecified reactive species

Jiong Tang,Menghuai Ma,Fan Liu,Xiaomei Yin,Haotian Shi,Qing Li,Kai Yang,Mengyue Yu

Advanced science (Weinheim, Baden-Wurttemberg, Germany) 11:e2400469 PubMed39076074

2024

Characterization of NiCas12b for In Vivo Genome Editing.

Applications

Unspecified application

Species

Unspecified reactive species

Yunqian Zhang,Jingjing Wei,Hongyan Wang,Yongming Wang

Nature communications 14:6885 PubMed37898598

2023

The Lin28b/Wnt5a axis drives pancreas cancer through crosstalk between cancer associated fibroblasts and tumor epithelium.

Applications

Unspecified application

Species

Unspecified reactive species

Zhaoqi Shu,Minghe Fan,Bo Tu,Zhiheng Tang,Haojie Wang,Haimeng Li,Hengchao Li,Meng Yuan,Jingru Bai,Sihan Huo,Lina Wang,Wei-Guo Zhu,Wei Wang,Xiaoyun Liu,Shaokun Shu,Ying Zhao

Cellular and molecular gastroenterology and hepatology 17:149-169 PubMed37717824

2023

Blockade of Hepatocyte PCSK9 Ameliorates Hepatic Ischemia-Reperfusion Injury by Promoting Pink1-Parkin-Mediated Mitophagy.

Applications

Unspecified application

Species

Unspecified reactive species

Yu Zhang,Ziyi Wang,Chenyang Jia,Wenjie Yu,Xiangdong Li,Nan Xia,Huiling Nie,Likalamu Pascalia Wikana,Minhao Chen,Yong Ni,Sheng Han,Liyong Pu

Cellular & molecular biology letters 28:66 PubMed37587410

2023

MiR-15b-5p and PCSK9 inhibition reduces lipopolysaccharide-induced endothelial dysfunction by targeting SIRT4.

Applications

Unspecified application

Species

Unspecified reactive species

Elisa Martino,Nunzia D'Onofrio,Anna Balestrieri,Luigi Mele,Celestino Sardu,Raffaele Marfella,Giuseppe Campanile,Maria Luisa Balestrieri

iScience 26:106916 PubMed37305703

2023

Targeting PCSK9 reduces cancer cell stemness and enhances antitumor immunity in head and neck cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Qi-Chao Yang,Shuo Wang,Yuan-Tong Liu,An Song,Zhi-Zhong Wu,Shu-Cheng Wan,Hui-Min Li,Zhi-Jun Sun

Journal of microbiology and biotechnology 32:1406-1415 PubMed36330745

2022

Silencing YY1 Alleviates Ox-LDL-Induced Inflammation and Lipid Accumulation in Macrophages through Regulation of PCSK9/ LDLR Signaling.

Applications

Unspecified application

Species

Unspecified reactive species

Zhengyao Qian,Jianping Zhao
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com